Translational & Precision Medicine (TPM) Network

Network Goals

Scientific Expertise:

The Translational & Precision Medicine (TPM) Network and associated Communities facilitate interactions among experts across multidisciplinary fields to foster translational science with a focus on individuals via patient care and society via healthcare. The interactions are through social media, email blasts, and teleconferences with focused scientific content.

Catalyst for Innovation:

The TPM Network is a catalyst for innovation by sponsoring a range of scientific programs at the Annual Meeting focused on translational and precision medicine.

Influence and Impact:

The TPM Network is the lead group engaged in translational and precision medicine and optimal pharmacotherapy in patient care.

Education and Communication:

The TPM Network offers educational opportunities via the Communities.

Organizational Effectiveness:

Leadership within TPM is expanded by a Network Steering Committee.
The TPM Network has regularly scheduled teleconferences and utilizes social media to engage members throughout the year.
The TPM Network fosters the career of its members by assisting Communities in recognizing members for individual achievements and contributions to ASCPT, sponsoring educational programming in translational and precision medicine, and providing opportunities for networking activities throughout an individual’s career.

ASCPT Members-Only Webinar presented by the Special Populations Community
Title: Recent Advances in Neonatal Clinical Pharmacology
Date and Time: Wednesday, December 11, 2019, 11:00 am ET
Speakers and Panelists: David Taft, PhD, and Khaled Abduljalil, PhD
Moderator: Farzaneh Salem, PharmD, PhD
Description: Neonates are one of the most challenging groups of patients when optimizing pharmacotherapy. This is partially due to the rapid physiological and maturational changes that occur in this population, as well as our limited knowledge of the impact of these changes on the pharmacokinetics and pharmacodynamics of drugs in neonates. Prematurity adds another layer of complexity. Clinical trials are seldom performed to establish appropriate dosing in this population. Modeling and simulation techniques and, more recently, physiologically based pharmacokinetic (PBPK) modeling have opened new prospects in the clinical management and dose selection for neonates. The major advances and challenges in modeling and simulations that enable prediction of pharmacokinetic and pharmacodynamics in neonates will be presented in this webinar. This presentation will include an overview of physiological changes in preterm neonates required to develop a PBPK model for preterm population as well as application of preterm PBPK models to predict pharmacokinetics and pharmacodynamics. Discussion will include the potential role of modeling and simulations in improving our understanding and dose optimization in this population. Lastly, a case study will be presented with the antibiotic medication gentamicin that illustrates how PBPK modeling can provide practitioners with a scientific rationale for dosage regimen selection in preterms, thereby promoting safe and effective therapeutic interventions in this patient population.
Registration Link: https://zoom.us/webinar/register/WN_2MTXQUwlRnCPW806DCgf9A

ASCPT Members-Only Webinar presented by the Membrane Transporter (MT) Community
Title: Novel Insights into the Etiology and Treatment of Drug-Induced Peripheral Neuropathy
Date and Time: Thursday, December 12, 2019, 1:00 PM ET
Speakers: Tore Bjerregaard Stage, PhD, and Shuiying Hu, PhD
Moderator: Caroline Lee, PhD
Description: Drug-induced peripheral neuropathy remains one of the dose limiting adverse reactions of multiple widely used anticancer drugs. Despite extensive effort in the past several decades, optimized benefit-risk profile for oncology product with neurotoxicity was not achieved. This webinar aims at presenting currently available strategies and ongoing exploratory pre-clinical research efforts, as well as human clinical trials, aiming to define a means of preventing and/or treating this side effect. This presentation will include: State-of-the-art novel in vitro technologies (e.g. iPSC-derived sensory neurons and Schwann cells) available to evaluate drug-induced peripheral neurotoxicity; recent insights into the transport mechanisms involved in the uptake and accumulation of neurotoxic chemotherapeutics into the peripheral nervous system, and on the prevention of neuropathy by transport inhibitors, explored by animal model and human clinical trial.
Registration Link: https://zoom.us/webinar/register/WN_fOApZ-VBTjGa9Mnq6NX_Ew

ASCPT Members-Only Webinar presented by the Infectious Diseases (INF) Community
Title: Clinical Pharmacology and Modeling and Simulation Applications in Neglected and/or Tropical Diseases
Date and Time: Wednesday, February 5, 2020, 1:00 pm ET
Speakers: Melanie Nicol, PharmD, PhD, and Luning (Ada) Zhuang, PhD
Moderators: Philip Sabato, MSc, PharmD
Description: This presentation will focus on applications and obstacles to clinical pharmacology research in tropical and neglected diseases. The unique opportunities and limitations to clinical pharmacology research in a resource limited setting will be discussed. Additionally, examples of drug repurposing to address neglected diseases and how clinical pharmacology can support these initiatives will be explored. A focus of the second speaker will be on Chagas disease- a neglected, tropical disease. Efficacy and safety data will be shared to provide context of dose recommendations in pediatric patients with Chagas Disease based on a model-informed approach.
Registration Link: https://zoom.us/webinar/register/WN_47YxyKgAQ6qPQMtM5LfyTw